Share price · MNKD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MNKD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+4.3%
Nothing announced by MNKD that day or the session before.
- 30 Sep 2026+16.8%
Nothing announced by MNKD that day or the session before.
- 2 Jul 2026+11.6%
Nothing announced by MNKD that day or the session before.
- 6 May 2026+24.5%
- 25 Feb 2026-36.8%
Nothing announced by MNKD that day or the session before.
- 16 Jan 2026-6.6%
Nothing announced by MNKD that day or the session before.
Share of unusual movement by asset
For each asset, the share of MNKD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | InsulinPeptide | Type 2 DiabetesType 1 Diabetes | |
| Approved | NKCC2Small molecule | Heart FailureChronic Kidney Disease | |
| Approved | IP receptor (prostacyclin pathway)Small molecule | Idiopathic Pulmonary FibrosisPulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $102M | $14M | $41M+ $55M short-term inv. | $23M-$35M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $109M | $18M | $53M+ $58M short-term inv. | $19M-$18M operating cash flow | report ↗ |
| 2026-Q1 | $90M | $17M | $53M+ $81M short-term inv. | $17M-$5.4M operating cash flow | report ↗ |
| 2025-Q3 | $82M | $14M | $127M+ $133M short-term inv. | —$24M operating cash flow | report ↗ |
| 2025-Q2 | $77M | $14M | $57M+ $122M short-term inv. | —$8.9M operating cash flow | report ↗ |
| 2025-Q1 | $78M | $11M | $47M+ $134M short-term inv. | —-$6.4M operating cash flow | report ↗ |
| 2024-Q3 | $70M | $13M | $62M+ $189M short-term inv. | —$9.3M operating cash flow | report ↗ |
| 2024-Q2 | $72M | $12M | $97M+ $151M short-term inv. | $2.0M$3.8M operating cash flow | report ↗ |
| 2024-Q1 | $66M | $10M | $193M+ $107M short-term inv. | —$6.7M operating cash flow | report ↗ |
| 2023-Q3 | $51M | $10.0M | $83M+ $58M short-term inv. | —$8.7M operating cash flow | report ↗ |
| 2023-Q2 | $49M | $6.5M | $86M+ $58M short-term inv. | $5.3M$2.6M operating cash flow | report ↗ |
| 2023-Q1 | $41M | $5.6M | $86M+ $80M short-term inv. | $9.8M$1.2M operating cash flow | report ↗ |
| 2022-Q3 | $33M | $4.1M | $54M+ $111M short-term inv. | $14M-$28M operating cash flow | report ↗ |
| 2022-Q2 | $19M | $4.9M | $36M+ $119M short-term inv. | $29M-$32M operating cash flow | report ↗ |
| 2022-Q1 | $12M | $3.5M | $67M+ $95M short-term inv. | $26M-$18M operating cash flow | report ↗ |
| 2021-Q3 | $22M | $3.7M | $52M+ $87M short-term inv. | $4.4M-$15M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $349M | $66M | $75M+ $96M short-term inv. | —$18M operating cash flow | report ↗ |
MannKind reported full-year 2025 revenue of $348.97M, up 22.2% YoY, with R&D spend of $66.35M, up 44.6% YoY. Cash and equivalents were $74.88M at year-end, and total cash, equivalents and investments were $176M. The company reported net income of $5.86M for the year.
During the period, MannKind completed its acquisition of scPharmaceuticals, adding Furoscix, which generated Q4 2025 net sales of $23M, up 91% YoY, while Afrezza Q4 net sales were $23M, up 25% YoY. Regulatory milestones include FDA acceptance of the Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and the Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. Enrollment is underway in the Nintedanib DPI Phase 1b INFLO-1 study with topline data expected in 2H 2026, and a Phase 2 trial in IPF is planned to enroll its first patient in Q2 2026. Other updates include preclinical development of Bumetanide DPI, formulation work on MNKD-1501 under the United Therapeutics collaboration, and Afrezza’s launch in India by Cipla.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $286M | $46M | $46M+ $151M short-term inv. | —$43M operating cash flow | report ↗ |
| 2023-FY | $199M | $31M | $238M+ $57M short-term inv. | $3.0M$34M operating cash flow | report ↗ |
| 2022-FY | $100M | $20M | $70M+ $101M short-term inv. | $22M-$81M operating cash flow | report ↗ |
| 2021-FY | $75M | $12M | $124M+ $80M short-term inv. | $20M-$62M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($259K), 13 sales ($3.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Friedman Michael A · director | Option exercise | 30,000 | $1.10 | $33K | Form 4 |
| 2026-11-17 | Friedman Michael A · director | Tax withholding | 8,109 | $4.07 | $33K | Form 4 |
| 2026-11-17 | Friedman Michael A · director | Option exercise (derivative) | 30,000 | — | — | Form 4 |
| 2026-09-25 | Binder Steven B. · director | Open-market sale | 39,051 | $3.29 | $128K | Form 4 |
| 2026-09-10 | Binder Steven B. · director | Open-market sale | 33,558 | $3.81 | $128K | Form 4 |
| 2026-08-07 | Binder Steven B. · director | Open-market sale | 39,051 | $4.06 | $159K | Form 4 |
| 2026-07-17 | Binder Steven B. · director | Open-market sale | 52,485 | $4.06 | $213K | Form 4 |
| 2026-07-17 | Thomson David · EVP Genl Counsel & Secretary | Open-market sale | 24,109 | $4.05 | $98K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 249 reporting institutions held 176.7M shares ($431.3M, 54.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 28,600,998 | $70.1M |
| 2 | STATE STREET CORP | 18,683,483 | $45.8M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 12,891,066 | $31.6M |
| 4 | UBS Group AG | 8,255,430 | $20.2M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 7,505,147 | $18.4M |
| 6 | MILLENNIUM MANAGEMENT LLC | 6,390,922 | $15.7M |
| 7 | Frazier Life Sciences Management, L.P. | 5,900,000 | $14.5M |
| 8 | MORGAN STANLEY | 5,793,147 | $14.2M |
| 9 | DIMENSIONAL FUND ADVISORS LP | 4,953,295 | $12.1M |
| 10 | 180 WEALTH ADVISORS, LLC | 4,291,703 | $10.5M |
| 11 | Rubric Capital Management LP | 3,620,413 | $8.9M |
| 12 | FMR LLC | 3,480,964 | $8.5M |
| 13 | BANK OF AMERICA CORP /DE/ | 3,383,677 | $8.3M |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 3,283,179 | $8.0M |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,171,824 | $7.8M |